Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 860

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 860
---
 the Debt Exchange Agreement, prior to the Contribution, the Company agreed to file, with the Secretary of State of the State of Delaware, a certificate of designations, in the form agreed in the Debt Exchange Agreement, to set forth the designations, powers, rights and preferences and qualifications, limitations and restrictions of the Series A Preferred Shares. Upon the occurrence of the Contribution and issuance of the Series A Preferred Shares to Scilex, the Outstanding Indebtedness shall be extinguished in its entirety and shall be of no further force or effect and shall be deemed paid and satisfied in full and irrevocably and automatically discharged, terminated and released. Note 8. Net Loss Per Share Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding for the period. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. Specifically, NSOs granted under the 2024 Plan to purchase an aggregate of 40,000,000 shares of the Company’s common stock were considered anti-dilutive and therefore were excluded from the computation of diluted net loss per share for the three months ended March 31, 2025. There were no outstanding securities considered anti-dilutive for computation of diluted net loss per share for the three months ended March 31, 2024.

|                                                                         |     | Three Months Ended 
 March 31,          |        2025 |   |     |   |        2024 |   |
|:------------------------------------------------------------------------|:----|:-------------------|------------:|:--|:----|:--|------------:|:--|
| Net loss (in thousands)                                                 |     | $                  |        (665 | ) |     | $ |      (1,506 | ) |
| Net loss per share — basic and diluted                                  |     | $                  |       (0.01 | ) |     | $ |       (0.01 | ) |
| Weighted average number of shares during the period — basic and diluted |     |                    | 160,000,000 |   |     |   | 160,000,000 |   |

Note 9. Subsequent Events Scilex Bio JV On April 17, 2025, Scilex and IPMC Company formed a joint venture, Scilex Bio, Inc. (“